ECP

Mallinckrodt Announces 2021 Advancing Extracorporeal Photopheresis Immunomodulation Investigator Award

Retrieved on: 
Friday, March 19, 2021
Medicine, Blood, Light therapy, Photopheresis, Mallinckrodt, ECP, Health sciences

DUBLIN, March 19, 2021 /PRNewswire/ --A project that will analyze the immunomodulatory effects of extracorporeal photopheresis therapy (ECP) through innate cells has won Mallinckrodt plc's 2021 Advances in ImmunomodulatoryECPresearch award.

Key Points: 
  • DUBLIN, March 19, 2021 /PRNewswire/ --A project that will analyze the immunomodulatory effects of extracorporeal photopheresis therapy (ECP) through innate cells has won Mallinckrodt plc's 2021 Advances in ImmunomodulatoryECPresearch award.
  • Research funded from the inaugural investigator award, which was founded in 2018 to mark the 30th anniversary of Mallinckrodt's pioneering THERAKOS ECP ImmunomodulationTM,was also presented at this year's EBMT.
  • Congratulating the winning team, Romano added: "As a pioneer in ECP immunomodulation, Mallinckrodt is proud to support the work of those who continue to investigate this exciting field of medicine.
  • The 2022 Advancing ECP Immunomodulation Investigator Award will be open for entries in September.

Mallinckrodt Announces Launch of 2020 Award in Support of Advancing ECP Immunomodulation

Retrieved on: 
Tuesday, October 22, 2019
Medicine, Clinical medicine, Health, Mallinckrodt, Immunomodulation, Photopheresis, MNK, ECP

STAINES-UPON-THAMES, United Kingdom, Oct. 222019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, has announced that its 2020 Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award is open for entries.

Key Points: 
  • STAINES-UPON-THAMES, United Kingdom, Oct. 222019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, has announced that its 2020 Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award is open for entries.
  • The award, now in its third year, was developed by Mallinckrodt to mark 30 years of its pioneering THERAKOS ECP Immunomodulation.
  • The Investigator Award reflects the company's ongoing commitment to the science of immunomodulation through ECP and its therapeutic applications.
  • "As a pioneer in ECP immunomodulation, Mallinckrodt established the ECP Immunomodulation Investigator Awardto recognise the efforts of those working in this exciting field of medicine.

Mallinckrodt Announces 2019 Investigator Award for Pioneering Efforts in ECP Immunomodulation

Retrieved on: 
Tuesday, March 26, 2019
Medicine, Mallinckrodt, Immunomodulation, Photopheresis, MNK, ECP, Health

STAINES-UPON-THAMES, England, March 26, 2019 /PRNewswire/ --Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the recipient of 2019's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award.

Key Points: 
  • STAINES-UPON-THAMES, England, March 26, 2019 /PRNewswire/ --Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the recipient of 2019's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award.
  • Mallinckrodt developed the Investigator Award to mark 30 years of its pioneering THERAKOS ECP Immunomodulation.
  • The Investigator Award reflects the company's ongoing commitment to the science of immunomodulation through ECP and its therapeutic applications.
  • The 2020 Advancing ECP Immunomodulation Investigator Award will be open for entries in September 2019.

Emergency Care Partners Merges with Progressive Emergency Physicians, Appoints Bill Yarbrough as CEO of Combined Business

Retrieved on: 
Monday, February 11, 2019
Health, Small business, Professional services, Accounting, Banking, Finance, Human resources, Legal, Other Professional Services, General Health, ECP, Limited liability partnership

Further, ECPs physicians including legacy physician partners from the former PEMM and PEPA groups and those from the newly absorbed PEP operations - will continue to be meaningful shareholders in the combined company.

Key Points: 
  • Further, ECPs physicians including legacy physician partners from the former PEMM and PEPA groups and those from the newly absorbed PEP operations - will continue to be meaningful shareholders in the combined company.
  • Shepard, Mullin, Richter & Hampton LLP acted as legal adviser to ECP and VHP, while Nexus Health Capital and Greenburg Traurig, P.A.
  • In addition to the PEP transaction, ECP appointed Bill Yarbrough as Chief Executive Officer of the Company and a member of the Companys Board of Directors, effective immediately.
  • Based in Pensacola, Florida, Emergency Care Partners (ECP) is a leading regional provider of emergency medicine and emergency department management services to hospitals and other free standing care facilities.